Cybin announces FDA authorization of IND for Kernal's Flow study of ketamine » 07:3810/2610/26/21
Cybin announced that the…
Cybin announced that the U.S. Food and Drug Administration has authorized an Investigational New Drug application to proceed with the Company's sponsored feasibility study using Kernel's Flow technology to measure ketamine's psychedelic effect on cerebral cortex hemodynamics. "The word psychedelic means 'mind-manifesting,' but what has been missing is useful 'mind-imaging'-the ability to dynamically trace the neural correlates of human conscious experience. Conventional neuroimaging just isn't dynamic enough to study the psychedelic experience in the brain as it happens. This study of ketamine's psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding," said Dr. Alex Belser, Cybin's Chief Clinical Officer. Leveraging Kernel's quantitative neuroimaging technology may lead to new frontiers in psychedelic therapeutics by enabling the acquisition of longitudinal brain activity before, during and after a psychedelic experience, providing quantification of what was previously subjective patient reporting. "Quantitatively measuring the brain within the context of a psychedelic experience is a promising frontier," said Bryan Johnson, founder and Chief Executive Officer of Kernel. "With Kernel Flow, Cybin's researchers can start putting numbers and quantification to subjective states of mind, including altered ones."
|Over a week ago|
Mindset expands benchmarking data for first generation psychedelices » 07:3510/1410/14/21
Mindset Pharma announced…
Mindset Pharma announced that, under its Co-operative Psychedelics Evaluation Platform program with InterVivo Solutions, the Company has further developed its first generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across LSD, psilocybin, and 5-MeO-DMT. The COPE Program is a translational testing platform developed in cooperation with InterVivo to introduce an industry standard against which the performance and efficacy of breakthrough psychedelic medicines are compared and assessed. Through this platform, Mindset and InterVivo intend to establish the first comprehensive psychedelics benchmark reference data set by evaluating a broad range of psychedelic drugs through a proprietary program of in vivo tests conducted at InterVivo's facility. The COPE program is anticipated to represent an invaluable tool to guide the development of next-generation psychedelic compounds and improve patentability and value in new molecule drug assets.
OTC Markets Group to hold a virtual conference » 08:4410/1310/13/21
CYBN, ENVB, FTRP, HUGE, MSSTF, TRYPF
KCSA Psychedelics Virtual…
KCSA Psychedelics Virtual Conference to be held on October 13-14 beginning at 9:45 am. Webcast Link
Fly Intel: After-Hours Movers » 18:4410/0410/04/21
NAPA, TISI, IVAC, LULU, CMTL, MGPI, CYBR, CYBN, RXDX, RVLV, TDUP, POSH
Check out this evening's…
Cybin initiated with an Outperform rating, $7 target at Oppenheimer » 16:1210/0410/04/21
Oppenheimer analyst Francois Brisebois initiated coverage of Cybin with an Outperform rating and $7 price target. The company's most advanced product, CYB001, consists of sublingual psilocybin for patients with major depressive disorder, or MDD, noted Brisebois, who is "encouraged" that the company's delivery system offers potential for faster onset and improved bioavailability. Although CYB001 is further along, he views CYB003 for alcohol use disorder, or AUD, as "the main reason to own" the stock. CYB003's proprietary deuterated new chemical entity "could offer the most scalable psychedelic treatment option as a result of rapid onset, controlled delivery, shorter duration, and reduced dependence on the healthcare system," the analyst said.
Cybin initiated with an Outperform at Oppenheimer » 16:0610/0410/04/21
Oppenheimer analyst Francois Brisebois initiated coverage of Cybin with an Outperform rating and $7 price target.
Cybin files C$125M mixed securities shelf 17:3010/0110/01/21
Cybin retains services of ROK Consulting » 07:5010/0110/01/21
Cybin announces it has…
Cybin announces it has retained the services of ROK Consulting, an investor communications and public relations company, to "play a key role in assisting the company enhance its market awareness, communications strategy, and engagement with leading financial and institutional market participants," the company said. ROK has agreed to comply with all applicable securities laws and the policies of all applicable stock exchanges in providing services to the company. Under the terms of the ROK engagement, which is for an initial three-month period, ROK will be paid $500,000 per month and will be granted options to acquire up to 500,000 common shares in the capital of the Company exercisable at a price of CDN$2.78 per share until December 31, 2022.
Cybin announces new additions, promotions in management team » 07:1010/0110/01/21
Cybin announces: the…
Cybin announces: the addition of Dr. Amir Inamdar as its Chief Medical Officer for its European Operations, the addition of Dr. Geoff Varty as its new Head of Research & Development, the promotion of Lori Challenger to Chief Compliance, Ethics & Administrative Officer, and the promotion of Robert Mino to General Counsel.
Mindset identifies two additional 5-MeO-DMT-inspired lead candidates » 07:4309/2909/29/21
Mindset Pharma announced…
Mindset Pharma announced that, in addition to its potential lead new chemical entity candidate, MSP-4018, the Company has identified two additional pipeline opportunities from its Family 4 compounds, MSP-4019 and MSP-4020. In preclinical studies, both compounds demonstrated strong efficacy and an improved safety profile in comparison to 5-MeO-DMT and parent compounds. Mindset's Family 4 compounds are DMT and 5-MeO-DMT-inspired novel drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.